Remepy完成3600万美元A轮融资，通过制药合作伙伴关系扩展其Hybrid Drug™产品管线，并推进帕金森病药物Hybridopa™的III期临床试验-动脉网

Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease

CISION 等信源发布 2026-08-12 20:30



可切换为仅中文







Funding brings total capital raised to $62 million as the Company expands pharmaceutical co-development partnerships and accelerates the Hybrid Drug category

本轮融资使公司累计募集资金总额达到6,200万美元，同时公司正扩大药物联合开发合作伙伴关系，并加速推进杂交药物（Hybrid Drug）品类的发展。

NEW YORK

纽约

，

Aug. 12, 2026

2026年8月12日

/PRNewswire/ --

/美通社/ --

Remepy

雷梅皮

, the pioneer of Hybrid Drugs, today announced the closing of a $36 million Series A financing round led by O.G. Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany, with participation of existing and new investors including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp..

混合药物领域的先驱企业今日宣布，已完成由O.G. Venture Partners和默克雪兰诺（德国达姆施塔特Merck KGaA的企业战略投资部门M Ventures）领投的3600万美元A轮融资，现有及新投资者包括NFX、Vine Ventures、Qumra Capital、TechAviv、97212 Ventures、Fresh Fund、PsyMed Ventures、Tadmor Group、Key1 Capital和IT-Farm Corp.等参与跟投。

The proceeds will accelerate the Company's pharmaceutical co-development partnerships and the expansion of its Hybrid Drug pipeline and platform, as well as fund the global Phase III clinical development of Hybridopa, Remepy's lead program for Parkinson's disease that will commence in Q4 2026. This funding brings the total capital raised by the Company to $62 million..

所得款项将加速公司药物联合开发合作伙伴关系，并推动其杂交药物（Hybrid Drug）产品管线及平台的扩展，同时为Remepy旗下针对帕金森病的领先项目Hybridopa的全球III期临床开发提供资金，该临床试验将于2026年第四季度启动。此次融资使公司累计筹集的资金总额达到6,200万美元。

Remepy partners with leading pharmaceutical companies to develop Hybrid Drugs, a new class of drugs that combine prescription medicines with personalized, AI-driven therapeutic apps. Hybrid Drugs integrate pharmacology with adaptive physical, cognitive, and behavioral interventions into a single treatment, enabling scalable, multidisciplinary care through the standard prescription model.

Remepy 与领先制药公司合作，开发“混合药物”这一新型药物类别，将处方药与个性化、人工智能驱动的治疗应用程序相结合。混合药物将药理学与自适应的物理、认知和行为干预整合为单一治疗方案，通过标准处方模式实现可扩展的多学科护理。

Beyond improving patient outcomes, the platform creates significant strategic value for pharmaceutical companies by generating new intellectual property, enabling lifecycle management, differentiating existing and future drugs, and potentially increasing clinical trial success through personalized integrative treatment..

除了改善患者疗效外，该平台还通过生成新的知识产权、支持产品生命周期管理、差异化现有及未来药物，并借助个性化整合治疗提高临床试验成功率，为制药公司创造重大的战略价值。

Supported by emerging FDA frameworks for drug-software combination products and regulatory alignment, the Hybrid Drug model is rapidly gaining industry momentum. The Company recently announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, to develop Hybrid Drugs across multiple indications, beginning with rare tumors..

得益于美国食品药品监督管理局（FDA）针对药械组合产品新兴框架的支持以及监管协调的推进，混合药物模型正迅速获得行业动力。该公司近期宣布与德国达姆施塔特的默克公司（Merck KGaA）达成战略合作，共同开发针对多种适应症的混合药物，首批聚焦于罕见肿瘤领域。

Hybridopa, Remepy's Hybrid Drug program for Parkinson's disease, has generated encouraging Phase IIa clinical results demonstrating improvements in both motor and non-motor symptoms, supported by peer-reviewed publications[i][ii] highlighting the biological mechanisms underlying the Hybrid Drug clinical effect.

Hybridopa 是 Remepy 公司针对帕金森病推出的混合药物（Hybrid Drug）项目，其二期a临床试验结果令人鼓舞，显示患者在运动症状和非运动症状方面均有改善；同行评审发表的研究文献[i][ii]进一步支持了这一结论，并阐明了该混合药物产生临床疗效的生物学机制。

The Company is now preparing the program for global Phase III development, expected to commence in Q4, 2026. Hybridopa is an investigational product and has not yet been approved by the FDA..

公司目前正在制定全球III期临床开发计划，预计于2026年第四季度启动。Hybridopa是一款在研产品，尚未获得美国食品药品监督管理局（FDA）批准。

Michal Tsur, PhD, and Or Shoval, Co-CEOs of Remepy

Remepy 联合首席执行官 Michal Tsur 博士和 Or Shoval

, 'We believe medicine is entering a new era, where every breakthrough drug will be paired with personalized intelligence to maximize its impact for every patient. Over the past year, we've demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment, and partnerships with leading pharmaceutical companies.

“我们相信，医学正步入一个新时代，每一款突破性药物都将与个性化智能相结合，以最大化其对每位患者的疗效。在过去的一年中，我们通过临床验证、同行评议的科学成果、监管协调以及与领先制药公司的合作，证明了这一愿景是可以实现的。”

This financing allows us to advance Phase III of Hybridopa for Parkinson's disease, and expand the Hybrid Drug model across multiple therapeutic areas.'.

这笔融资使我们能够推进针对帕金森病的Hybridopa项目第三阶段，并在多个治疗领域扩展混合药物模式。

Ziv Kop, Managing Partner at O.G. Venture Partners (Israel)

齐夫·科普，O.G. Venture Partners（以色列）管理合伙人

, 'We're excited to lead Remepy's Series A and support an exceptional team pioneering a new category of medicine. By bringing together biotechnology, AI, and digital health, Remepy is redefining how medicines are developed and delivered. With compelling clinical data, growing regulatory momentum, and strong validation from leading pharmaceutical partners, we believe Hybrid Drugs have the potential to transform patient care - and we're proud to support Remepy in its next phase of growth.'.

“我们很高兴能领投Remepy的A轮融资，并支持这支在开创全新药物类别方面表现卓越的团队。通过融合生物技术、人工智能和数字健康，Remepy正在重新定义药物的研发与交付方式。凭借令人信服的临床数据、日益增强的监管势头以及来自领先制药合作伙伴的有力验证，我们相信混合药物具有变革患者护理的潜力——我们为荣能在Remepy的下一增长阶段提供支持。”

Dr. Eyal Ben Ami, Scientific Lead at M Ventures,

M Ventures 科学负责人 Eyal Ben Ami 博士，

'Remepy's pioneering Hybrid Drugs approach reflects the growing importance and applicability of integrating AI into the delivery of health and physical medicines. Our investment from M Ventures is intended to further enable the company, underscoring our belief that this new class of medicine - that combines innovative therapeutics with AI-driven, patient-centered care - has the potential to redefine medicine.

Remepy开创性的“混合药物”方法，反映了将人工智能整合到健康和实体药物交付中的日益增长的重要性和适用性。我们通过M Ventures进行的投资旨在进一步赋能该公司，这凸显了我们的信念：这一新型药物类别——将创新疗法与以人工智能驱动、以患者为中心的护理相结合——有望重新定义医学。

We look forward to advancing it across multiple drug classes and disease areas.'.

我们期待在多个药物类别和疾病领域推进其发展。

Gigi Levi-Weiss, founding partner at NFX

吉吉·利维-韦斯，NFX 创始合伙人

, 'We've believed in Remepy's vision since day one. The team's ability to translate bold ideas into clinical and commercial momentum has only strengthened our conviction, and we're excited to continue supporting the company as it enters its next stage of growth.'

“自第一天起，我们就坚信Remepy的愿景。团队将大胆创意转化为临床和商业推动力的能力，进一步坚定了我们的信心。我们很高兴能在公司进入下一个增长阶段之际继续提供支持。”

About Remepy

关于 Remepy

Remepy is pioneering Hybrid Drugs, a new class of drugs combining traditional drugs with personalized, AI-driven therapeutic apps. Remepy partners with leading pharma companies to bring to market Hybrid Drugs, that integrate pharmacology with adaptive physical, cognitive, and behavioral interventions into a single treatment, enabling scalable, multidisciplinary care within a standard drug prescription model. Supported by emerging FDA frameworks for drug–software combination products and strong clinical data, this model is rapidly gaining traction.

Remepy 正在开创“混合药物”这一全新药物类别，将传统药物与个性化的、由人工智能驱动的治疗应用程序相结合。Remepy 与领先制药公司合作，推动混合药物上市；这类药物将药理学与自适应的物理、认知和行为干预整合为单一治疗方案，从而在标准处方药模式下实现可扩展的多学科护理。得益于美国食品药品监督管理局（FDA）针对药械组合产品新兴的监管框架以及强有力的临床数据支持，该模式正迅速获得市场认可。

Remepy's lead program, Hybridopa for Parkinson's, is entering Phase III following strong Phase IIa results. Remepy is turning drugs into intelligent, software-enabled, adaptive treatment platforms. For additional information, please visit: .

Remepy的领先项目——用于帕金森病的Hybridopa，在取得强劲的IIa期临床试验结果后，正进入III期临床试验。Remepy正在将药物转化为由软件赋能的智能、自适应治疗平台。欲了解更多信息，请访问：。

https://www.remepy.com/

About

关于

O.G. Venture Partners

O.G. 风险投资合伙人

O.G. Venture Partners (OGVP) is a global, single-LP venture capital fund founded in 2017 and backed by Eyal Ofer's Ofer Global, and focused primarily on early growth-stage investments, typically in Series B and C rounds. OGVP manages over $1.5 billion in assets under management (AUM). Its active portfolio includes companies such as Lendbuzz, Coralogix, Via, Neko Health, Connecteam, Peregrine, Superplay, and Buildots, among others..

O.G. Venture Partners（OGVP）是一家全球性的单一有限合伙人风险投资基金，成立于2017年，由埃亚尔·奥弗（Eyal Ofer）旗下的Ofer Global支持，主要专注于早期成长阶段的投资，通常为B轮和C轮融资。OGVP管理的资产规模（AUM）超过15亿美元。其活跃投资组合包括Lendbuzz、Coralogix、Via、Neko Health、Connecteam、Peregrine、Superplay和Buildots等公司。

About M Ventures

关于 M Ventures

M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success.

M Ventures 是德国达姆施塔特默克集团（Merck KGaA）的战略企业风险投资部门。M Ventures 总部位于荷兰，并在德国、美国和以色列设有办事处，在全球范围内投资于由创新型企业家驱动的变革性理念。M Ventures 积极赋能其投资组合公司，与管理团队及共同投资者携手合作，将科学发现转化为商业成功。

M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck KGaA, Darmstadt, Germany's current and future businesses..

M Ventures 专注于通过创立公司和进行股权投资，识别并资助针对某些最具挑战性难题的创新解决方案，其投资领域旨在影响德国达姆施塔特默克集团（Merck KGaA）当前及未来业务的生命力与可持续性。

http://www.m-ventures.com/

About NFX

关于 NFX

NFX invests in seed and pre-seed founders building the next generation of category-defining companies. Our five General Partners have founded ten companies with more than $10 billion in combined exits. Since launching in 2017, we've backed 25 unicorns across San Francisco, Silicon Valley, and Israel.

NFX 投资于种子轮和预种子轮的创始人，助力他们打造下一代定义品类的公司。我们的五位普通合伙人曾创立十家公司，累计退出金额超过 100 亿美元。自 2017 年成立以来，我们已在旧金山、硅谷和以色列支持了 25 家独角兽企业。

NFX manages $1.5B in assets, and we are actively investing out of our fourth fund..

NFX 管理着 15 亿美元的资产，我们正积极从第四只基金中进行投资。

Media contact:

媒体联系人：

Tsipi Haitovsky

齐皮·海托夫斯基

Global Media Liaison

全球媒体联络人

Remepy

雷梅皮

[email protected]